Malaria Vaccine: CSP-rEPA

设计、合成了恶性疟原虫环子孢子蛋白(CS)基因，并将其克隆到大肠杆菌和巴斯德毕赤酵母表达载体中。获得了一个与恶性疟原虫印度株相应序列的重组CS蛋白(RCSP)。该蛋白将被连接到载体蛋白，例如来自aruginosa的重组外源蛋白A和连接的Pfs25。在毕赤酵母表达系统中继续努力产生CSP。 正在开发一种使用在子孢子表面表达恶性疟原虫CSP的转基因伯氏原虫的小鼠模型，并进行测试，以评估基于CSP的疫苗所提供的保护作用。我们还创建了一种转基因Knowelsi寄生虫，在其子孢子表面表达恶性疟原虫CSP，以建立一个猴子挑战模型，用于评估基于CSP的疫苗的保护效果。

Several genes encoding the Plasmodium falciparum Circumsporozoite (CS) protein has been designed, synthesized, and cloned into an E. coli and P. pastoris expression vectors. One recombinant CS protein (rCSP) with sequence corresponding to P. falciparum strain India was produced. The protein will be conjugated to carrier proteins, e.g. a recombinant exoprotein A from Pseudomonas aruginosa, and conjugated Pfs25. Efforts continue to produce the CSP in the Pichia pastoris expression system. A mouse model using a transgenic berghei parasite expressing falciparum CSP on its sporozoite surface is being developed and tested as an assay to evaluate protection imparted by a CSP-based vaccine. We are also creating a transgenic knowelsi parasite, expressing falciparum CSP on its sporozoite surface, to establish a monkey challenge model for evaluating protective efficacy of CSP-based vaccines.